{
  "pmcid": "10125117",
  "sha256": "fc2b00cbe74982ccdbd3eea220d41bbb236f85730f6979f601c42d7d2af148e6",
  "timestamp_utc": "2025-11-09T21:51:44.736110+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.160932452276064,
    "reading_ease": 37.50608786098877,
    "word_count": 227
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Sitagliptin for Prevention of Posttransplant Diabetes Mellitus"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This single-center, randomised, double-blind, placebo-controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults aged 18 years or older who received a kidney transplant and exhibited postoperative hyperglycemia."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised using block randomisation to receive sitagliptin or placebo"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the efficacy of sitagliptin in preventing PTDM in kidney transplant recipients."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the improvement of 2-hour oral glucose tolerance test (OGTT) by >20 mg/dL at 3 months posttransplant."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Participants were randomised using block randomisation to receive sitagliptin or placebo, with allocation concealed by a research pharmacist."
      },
      "Blinding": {
        "score": 3,
        "evidence": "double-blind"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Sixty-one patients were randomised, 32 to sitagliptin and 29 to placebo."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Fifty patients were analysed using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "At 3 months, the 2-hour OGTT was 141.00 ± 62.44 mg/dL in the sitagliptin group and 165.22 ± 72.03 mg/dL in the placebo group (p = 0.218)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Sitagliptin was well tolerated, with similar adverse event rates in both groups."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT01928199."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 22,
    "max_score": 25
  }
}